|
May 1
|
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results
|
|
May 1
|
Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?
|
|
Mar 17
|
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
|
|
Mar 14
|
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
|
|
Mar 14
|
High Growth Tech Stocks in Europe to Watch This March 2025
|
|
Mar 13
|
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
|
|
Mar 13
|
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
|
|
Mar 12
|
Roche, Zealand sign deal: What it means for weight loss drug space
|
|
Mar 12
|
Novo Nordisk Is Falling. Competition Is a Killer.
|
|
Mar 12
|
Novo Nordisk, Starbucks shares slumping: Trending Tickers
|
|
Mar 12
|
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%
|
|
Mar 12
|
Novo Nordisk Stock Slides After Roche Strikes Weight-Loss Deal
|
|
Mar 12
|
Zealand Pharma, Roche have 2 best-in-class obesity assets, CEO tells Investing.com
|
|
Mar 12
|
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug
|
|
Mar 12
|
Roche secures Zealand obesity drug candidate for up to $5.3 billion
|
|
Mar 12
|
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
|
|
Feb 21
|
Zealand Pharma AS (ZLDPF) Q4 2024 Earnings Call Highlights: Strong Cash Position and Obesity ...
|
|
Feb 20
|
Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
|
|
Feb 20
|
Zealand Pharma convenes its Annual General Meeting 2025
|
|
Feb 20
|
Correction: Zealand Pharma Announces Financial Results for the Full Year 2024
|